

Press release

Stockholm, 19 October 2026

Sobi to present new Aspaveli®/Empaveli® data at ASN Kidney Week 2026

Sobi® today announced that seven abstracts on Aspaveli/Empaveli (pegcetacoplan) have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2026, taking place from 21–25 October in Denver, Colorado, USA. The programme includes two oral and five poster presentations covering longer-term clinical outcomes, renal safety and treatment experience, alongside the phase IV PRISM-C3 study, reflecting Sobi's commitment to generating real-world evidence.

The two oral presentations will report 76-week outcomes with Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), demonstrating maintenance of proteinuria reduction and eGFR stabilisation. These include a paediatric subgroup analysis from VALIANT and its VALE extension.

“Longer-term follow-up is important to deepen our understanding of treatment outcomes for people living with C3G and primary IC-MPGN,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. “The 76-week analyses, including findings in adolescent patients, continue to build the evidence base for Aspaveli/Empaveli. Alongside research into renal safety, treatment experience and use in kidney transplant recipients, the presentations at ASN reflect our commitment to addressing the needs of people living with these rare kidney diseases.”

Oral presentations	
Pegcetacoplan for 76 Weeks Maintains Proteinuria Reduction and eGFR Stabilization for Pediatric Patients: VALIANT+VALE Subgroup Analysis	Session: Glomerular Diseases: Epidemiology and Real-World Outcomes [OR1402-1] October 22, 2026, 05:30 PM - 05:40 PM Location: Room 501, Convention Center
Pegcetacoplan for 76 Weeks Maintains Proteinuria Reduction and Stabilizes Kidney Function in C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)	Session: Glomerular Diseases: Clinical Trial Results [OR1402-3] October 24, 2026, 05:50 PM - 06:00 PM Location: Mile High Ballroom 4A, Convention Center

Poster presentations	
PRESERVE-C3Tx, a Phase 3b Pilot Study Design: Effect of Preemptive Pegcetacoplan Use on Recurrence of C3 Glomerulopathy or Primary Immune Complex-Membranoproliferative Glomerulonephritis in Kidney Transplant Recipients	October 22, 2026 from 10:00 AM to 12:00 PM Session: Informational Posters – 1 INFO21-TH
Renal Safety of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH): Findings from Clinical Trials and Global Real-World Experience	Session: AKI: Biomarkers, Diagnostics, and Risk Prediction [PO0102-2] October 23, 2026 from 10:00 AM to 12:00 PM
User Experience with Pegcetacoplan On-Body Injector in Patients with C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis	Session: Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other [PO1402-07] October 24, 2026 from 10:00 AM to 12:00 PM
Pharmacokinetic (PK), pharmacodynamic (PD) and exposure–response (E–R) analysis of pegcetacoplan in C3 glomerulopathy (C3G) & primary immune-complex membranoproliferative glomerulonephritis (pIC-MPGN)	Session: Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other [PO1402-07] October 24, 2026 from 10:00 AM to 12:00 PM
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis: PRISM-C3, a Multi-Country Phase 4 Study	October 24, 2026 from 10:00 AM to 12:00 PM Session: Informational Posters -3 [INFO17-SA]

All times are local to Denver. Oral presentation times refer to the full sessions.

About Aspaveli®/Empaveli® (pegcetacoplan)

Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b therapy designed to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases. It is the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older approved in the United States, European Union, and other countries globally. Aspaveli/Empaveli is also approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the United States, European Union, and other countries globally.

About the Sobi® and Apellis (now part of Biogen) collaboration

Apellis (now part of Biogen) and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan. Apellis (now part of Biogen) has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and [LinkedIn](https://www.linkedin.com/company/sobi).

Contacts

For details on how to contact the Sobi Investor Relations Team, please click [here](#). For Sobi Media contacts, click [here](#).

Swedish Orphan Biovitrum AB (publ) (Sobi®)

SE-112 76 Stockholm, Sweden
Visiting address: Norra Stationsgatan 93A, Stockholm, Sweden
+46 8 697 20 00 | info@sobi.com | sobi.com